联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4142人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313821, encodeId=e9e813138213c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效, objectType=article, longId=207272, objectId=f72f20e272b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72f20e272b6, replyNumber=0, likeNumber=165, createdTime=2021-02-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72f20e272b6, moduleTitle=ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72f20e272b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313820, encodeId=f481131382036, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, objectType=article, longId=206376, objectId=d9952063e6c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9952063e6c2, replyNumber=0, likeNumber=68, createdTime=2021-01-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9952063e6c2, moduleTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9952063e6c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313819, encodeId=56ac1313819ac, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=邢宝才教授：生存期翻倍，“T+A”免疫联合治疗推动晚期肝癌系统性治疗获得飞跃, objectType=article, longId=206321, objectId=461320632130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461320632130, replyNumber=0, likeNumber=103, createdTime=2021-01-29, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461320632130, moduleTitle=邢宝才教授：生存期翻倍，“T+A”免疫联合治疗推动晚期肝癌系统性治疗获得飞跃, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461320632130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313818, encodeId=cbf413138188d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量, objectType=article, longId=206250, objectId=56f72062509e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f72062509e, replyNumber=0, likeNumber=93, createdTime=2021-01-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f72062509e, moduleTitle=JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f72062509e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313817, encodeId=aa70131381efe, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Nat Commun：BRD4介导p53抑制作用是急性髓性白血病的联合治疗靶标, objectType=article, longId=205873, objectId=3c432058e396, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c432058e396, replyNumber=0, likeNumber=65, createdTime=2021-01-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c432058e396, moduleTitle=Nat Commun：BRD4介导p53抑制作用是急性髓性白血病的联合治疗靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c432058e396)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, objectType=article, longId=205673, objectId=6fbf2056e3fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf2056e3fc, replyNumber=0, likeNumber=81, createdTime=2021-01-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf2056e3fc, moduleTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf2056e3fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313815, encodeId=3dcd131381522, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较, objectType=article, longId=205265, objectId=52e920526519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52e920526519, replyNumber=0, likeNumber=140, createdTime=2021-01-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52e920526519, moduleTitle=Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52e920526519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313814, encodeId=b19013138144b, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Dermatolog Treat：长脉冲Nd-Yag激光与伊曲康唑联合治疗甲癣的临床效果更佳，患者满意度高, objectType=article, longId=204441, objectId=11d820444145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11d820444145, replyNumber=0, likeNumber=95, createdTime=2020-12-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11d820444145, moduleTitle=J Dermatolog Treat：长脉冲Nd-Yag激光与伊曲康唑联合治疗甲癣的临床效果更佳，患者满意度高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11d820444145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313813, encodeId=37cb131381338, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, objectType=article, longId=204048, objectId=2fa5204048fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fa5204048fb, replyNumber=0, likeNumber=81, createdTime=2020-12-04, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fa5204048fb, moduleTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fa5204048fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313812, encodeId=6c35131381280, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAMA Psychiatry：重度抑郁症的药物和心理序贯联合治疗, objectType=article, longId=203939, objectId=2d252039390f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d252039390f, replyNumber=0, likeNumber=60, createdTime=2020-12-02, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d252039390f, moduleTitle=JAMA Psychiatry：重度抑郁症的药物和心理序贯联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d252039390f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313811, encodeId=f8cd1313811cf, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：羟氯喹或羟氯喹与阿奇霉素联合治疗新冠肺炎效果不显著, objectType=article, longId=203561, objectId=41b120356188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41b120356188, replyNumber=0, likeNumber=65, createdTime=2020-11-21, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41b120356188, moduleTitle=NEJM：羟氯喹或羟氯喹与阿奇霉素联合治疗新冠肺炎效果不显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41b120356188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313810, encodeId=cf00131381091, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, objectType=article, longId=203464, objectId=b4f620346485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f620346485, replyNumber=0, likeNumber=68, createdTime=2020-11-17, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f620346485, moduleTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f620346485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313809, encodeId=881e13138091f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=促进2019CCEP专家建议落地，强调联合治疗，推动超高危患者风险管理改善, objectType=article, longId=202991, objectId=dc4c2029918f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc4c2029918f, replyNumber=0, likeNumber=105, createdTime=2020-11-08, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc4c2029918f, moduleTitle=促进2019CCEP专家建议落地，强调联合治疗，推动超高危患者风险管理改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc4c2029918f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313808, encodeId=e4051313808f9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=罗氏泰圣奇®免疫联合治疗方案在中国获批用于治疗肝细胞癌, objectType=article, longId=202585, objectId=09a2202585ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09a2202585ad, replyNumber=0, likeNumber=71, createdTime=2020-10-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09a2202585ad, moduleTitle=罗氏泰圣奇®免疫联合治疗方案在中国获批用于治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09a2202585ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313807, encodeId=9197131380e2f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=55, createdTime=2020-10-24, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313806, encodeId=c951131380619, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, objectType=article, longId=201940, objectId=9263201940fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9263201940fd, replyNumber=0, likeNumber=83, createdTime=2020-10-12, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9263201940fd, moduleTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9263201940fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313805, encodeId=98bf13138054c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后, objectType=article, longId=201449, objectId=7c8f201449ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c8f201449ff, replyNumber=0, likeNumber=77, createdTime=2020-10-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c8f201449ff, moduleTitle=Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c8f201449ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313804, encodeId=dd25131380404, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Nat Med：抗HIV-1抗体联合治疗与病毒特异性T细胞免疫力增强相关, objectType=article, longId=201414, objectId=04e72014140f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04e72014140f, replyNumber=0, likeNumber=91, createdTime=2020-10-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04e72014140f, moduleTitle=Nat Med：抗HIV-1抗体联合治疗与病毒特异性T细胞免疫力增强相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04e72014140f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313803, encodeId=4e671313803bc, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=杨勇教授：替雷利珠单抗在尿路上皮癌一线免疫联合治疗展示曙光, objectType=article, longId=201006, objectId=cac3201006d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cac3201006d4, replyNumber=0, likeNumber=86, createdTime=2020-09-23, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cac3201006d4, moduleTitle=杨勇教授：替雷利珠单抗在尿路上皮癌一线免疫联合治疗展示曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cac3201006d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313802, encodeId=25e4131380280, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAMA：维生素C、皮质类固醇和维生素B1联合治疗对脓毒性休克患者器官衰竭的影响, objectType=article, longId=199815, objectId=fbf3199815d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbf3199815d2, replyNumber=0, likeNumber=74, createdTime=2020-08-24, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbf3199815d2, moduleTitle=JAMA：维生素C、皮质类固醇和维生素B1联合治疗对脓毒性休克患者器官衰竭的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效

2021-02-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效

2021-01-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

邢宝才教授：生存期翻倍，“T+A”免疫联合治疗推动晚期肝癌系统性治疗获得飞跃

2021-01-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量

2021-01-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Nat Commun：BRD4介导p53抑制作用是急性髓性白血病的联合治疗靶标

2021-01-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益

2021-01-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较

2021-01-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Dermatolog Treat：长脉冲Nd-Yag激光与伊曲康唑联合治疗甲癣的临床效果更佳，患者满意度高

2020-12-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤

2020-12-04

仁心济世 (审核中...)

前往app查看评论内容

#联合治疗#

JAMA Psychiatry：重度抑郁症的药物和心理序贯联合治疗

2020-12-02

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：羟氯喹或羟氯喹与阿奇霉素联合治疗新冠肺炎效果不显著

2020-11-21

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究

2020-11-17

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

促进2019CCEP专家建议落地，强调联合治疗，推动超高危患者风险管理改善

2020-11-08

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

罗氏泰圣奇®免疫联合治疗方案在中国获批用于治疗肝细胞癌

2020-10-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2020-10-24

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征

2020-10-12

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后

2020-10-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Nat Med：抗HIV-1抗体联合治疗与病毒特异性T细胞免疫力增强相关

2020-10-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

杨勇教授：替雷利珠单抗在尿路上皮癌一线免疫联合治疗展示曙光

2020-09-23

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JAMA：维生素C、皮质类固醇和维生素B1联合治疗对脓毒性休克患者器官衰竭的影响

2020-08-24

科室
- - 订阅+
  - 更多科室
工具
服务